Bilirubin Kinetic Modeling for Quantification of Extracorporeal Liver Support

Institut of Physiology, Center for Physiological Medicine, Medical University of Graz, Graz, Austria.
Blood Purification (Impact Factor: 1.28). 02/2006; 24(4):413-22. DOI: 10.1159/000094575
Source: PubMed


To provide a measure of treatment dose for extracorporeal liver support (ELS).
The kinetics of conjugated bilirubin were described by a two-compartment model (Vc, Vp) with central elimination (K) and constant generation rate (G). The transfer of solute between compartments was modeled by intercompartmental clearance (Kpc). The central compartment (Vc) was assumed as a constant fraction of total volume (Vc = 0.3*Vt).
Eight patients were studied during 35 treatments lasting 6 h each. The average K, Vt, Kpc, G, and mass of conjugated bilirubin removed were 18.6 +/- 3.9 ml/min, 9.1 +/- 3.8 liters, 103 +/- 108 ml/min, 0.33 +/- 0.15 mg/min, and 641 +/- 275 mg, respectively. The reduction ratio (48 +/- 10%) measured as the change in post- to pre-treatment concentrations underestimated the modeled fraction of bilirubin mass removed (54 +/- 13%) essentially because of significant conjugated bilirubin appearance during treatments.
Kinetic analysis provides an improved measure of treatment dose as generation, distribution, and elimination of conjugated bilirubin are jointly considered.

13 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The elimination of protein-bound solutes during extracorporeal liver support (ELS) therapy involves a sequence of steps and processes such as diffusion, convection, filtration, and adsorption. It was the purpose of this study to analyze the time course and the relative contribution of these processes to overall solute removal. Eighteen treatments done in 8 acute-on-chronic liver failure patients for a duration of 8 h using fractionated plasma separation and adsorption (FPSA) were studied. Conjugated bilirubin was measured in the extracorporeal circulation at 6 different sampling points in regular intervals. Clearance and removal rates were calculated for the whole system and for selected system components. Conjugated bilirubin concentrations decreased in the primary circuit directly connected to the patient and remained stable or increased in the secondary circuit which contained the adsorbers. Bilirubin clearance declined notably during the first 2 h of therapy for the whole system as well as for the adsorbers. The clearance for bilirubin in the primary circuit provided by the FX50 dialyzer was relatively small but constant. In the secondary circuit clearance was larger for the anion exchanger (Prometh02TM) than for the neutral resin (Prometh01TM) and decreased throughout the ELS treatment. Thus, approximately 90% of overall removal rate for conjugated bilirubin occurred in the adsorbers and about 10% in the dialyzer. The information obtained on the relative contribution of different ELS components to overall bilirubin removal could be helpful to improve the performance of selected components of FPSA and thereby of ELS as a whole.
    IFMBE proceedings 01/2009; 25(7). DOI:10.1007/978-3-642-03885-3_172
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract
  • [Show abstract] [Hide abstract]
    ABSTRACT: Artificial extracorporeal liver support or 'liver dialysis' has been used in patients with severe liver failure with increasing frequency since the Molecular Adsorbents Recirculating System (MARS), a variant of albumin dialysis, was introduced in 1999. Nevertheless, liver dialysis must still be thought of as experimental because its contribution to improved patient survival has not been proven in large randomized trials. Prometheus is a novel device for fractionated plasma separation via an albumin-permeable filter that was developed to improve removal of albumin-bound toxins. Initial studies have proven clinical use of Prometheus to be feasible and safe. Head-to-head comparisons of Prometheus and MARS have shown treatment with the former to be more efficient with respect to removal of most albumin-bound and water-solved markers. As controlled studies with clinical end points are lacking, it is not known whether the observed greater detoxification capacity of Prometheus will translate into clinical benefit; two small studies indicate that there might be a beneficial effect in hepatic encephalopathy and pruritus. In a recent randomized comparison of MARS and Prometheus, however, hemodynamic improvement was observed in response to MARS, but not Prometheus, treatment. A large randomized controlled trial investigating the effect of Prometheus on survival--the HELIOS study--has been initiated. First results are expected in 2008 and will be crucial to establishing a role for Prometheus in the field of extracorporeal liver support.
    Nature Clinical Practice Nephrology 06/2007; 3(5):267-76. DOI:10.1038/ncpneph0466 · 6.08 Impact Factor
Show more

Similar Publications